MARKET

PRNB

Principia Biopharma
PRNB
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-47.9465
61.84
9.44
3,325,283,410.80
News
Financial
Releases
Corp Actions
Analysis
Profile
Merger Arbitrage - Q3 2020 Ends With A Big Bang
Merger activity increased significantly last week with ten new deals announced.The merger of WPX Energy (WPX) and Devon Energy Corporation (DVN).Morgan Stanley (MS) completes the acquisition of E*TRADE Financial Corporation (ETFC).
Seekingalpha · 10/09 04:58
Hedge Funds Keep Buying Principia Biopharma Inc. (PRNB)
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend
Insider Monkey · 09/29 02:00
Merger Arbitrage Mondays - A Very Active Quarter Draws To A Close
Merger activity increased last week with one new deal announced.The acquisition of Standard AVB Financial by Dollar Mutual Bancorp.InnerWorkings receives shareholder approval.
Seekingalpha · 09/28 16:04
READ NOW: Monteverde & Associates PC Investigates the Merger
NEW YORK, NY / ACCESSWIRE / September 19, 2020 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: * Maxim Integrated Products, Inc.
ACCESSWIRE · 09/19 14:40
dosing underway for Principia's rilzabrutinib mid-stage study in IgG4-related disease
Principia Biopharma (PRNB) has dosed the first patient in an open label two-arm Phase 2A trial, evaluating rilzabrutinib in IgG4-related disease ((RD)), an immune-mediated fibroinflammatory condition that is capable of affecting
Seekingalpha · 09/17 13:08
Principia Announces First Patient Dosed In Phase 2A Trial Of Rilzabrutinib In IgG4-Related Disease
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today
Benzinga · 09/17 12:04
Monteverde & Associates Reminds Shareholders of its Ongoing Investigation Regarding the Merger
NEW YORK, NY / ACCESSWIRE / September 15, 2020 / Juan Monteverde, founder, and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: * Pfenex Inc.
ACCESSWIRE · 09/15 14:35
Neoleukin Therapeutics Announces Appointment of Martin Babler to Board of Directors
SEATTLE, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Martin Babler, President and Chief Executive Officer
GlobeNewswire · 09/10 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRNB. Analyze the recent business situations of Principia Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRNB stock price target is 86.00 with a high estimate of 100.00 and a low estimate of 72.00.
EPS
Institutional Holdings
Institutions: 180
Institutional Holdings: 33.81M
% Owned: 101.73%
Shares Outstanding: 33.24M
TypeInstitutionsShares
Increased
54
3.21M
New
47
306.51K
Decreased
38
2.38M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.58%
Pharmaceuticals & Medical Research
+0.69%
Key Executives
Chairman/Independent Director
Alan Colowick
President/Chief Executive Officer/Director
Martin Babler
Chief Financial Officer
Christopher Chai
Chief Scientific Officer
David Goldstein
Senior Vice President
Wu Liana
Vice President
Ken Brameld
Other
Roy Hardiman
Other
Dolca Thomas
Other
Stefani Wolff
Independent Director
Dan Becker
Independent Director
Simeon George
Independent Director
Shao-Lee Lin
Director
C. Patrick Machado
Independent Director
Patrick Machado
Independent Director
Shawn Tomasello
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Principia Biopharma stock information, including NASDAQ:PRNB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRNB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRNB stock methods without spending real money on the virtual paper trading platform.